5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Impact of Portable Normothermic Blood-Based Machine Perfusion on Outcomes of Liver Transplant : The OCS Liver PROTECT Randomized Clinical Trial

      research-article
      , MD, PhD 1 , , , MD, PhD 2 , , MD, PhD 3 , , MD 4 , , MD 5 , , MD 6 , , MD 7 , , MD 8 , , MD 9 , , MD 10 , , MD 11 , , MD 12 , , MD 13 , , MD 14 , , MD 15 , , MD 16 , , MD 17 , , MD 18 , , MD 19 , , MD 20 , , MD, PhD 1 , , MD 2 , , MD 3 , , MD 4 , , MD 5 , , MD 8 , , MD 9 , , MD 10 , , MD 14 , , MD 16 , , MD 18 , , MD 19 , , MD 1 , , MD 21 , , MD 21
      JAMA Surgery
      American Medical Association

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          Can oxygenated portable normothermic perfusion of deceased donor livers for transplant improve outcomes compared with the current standard of care using ischemic cold storage?

          Findings

          In this multicenter randomized clinical trial of 300 recipients of liver transplants with the donor liver preserved by either normothermic perfusion or conventional ischemic cold storage, normothermic machine perfusion resulted in decreased early liver graft injury and ischemic biliary complications and greater organ utilization.

          Meaning

          In this study, portable normothermic oxygenated machine perfusion of donor liver grafts resulted in improved outcomes after liver transplant and in more livers being transplanted.

          Abstract

          Importance

          Ischemic cold storage (ICS) of livers for transplant is associated with serious posttransplant complications and underuse of liver allografts.

          Objective

          To determine whether portable normothermic machine perfusion preservation of livers obtained from deceased donors using the Organ Care System (OCS) Liver ameliorates early allograft dysfunction (EAD) and ischemic biliary complications (IBCs).

          Design, Setting, and Participants

          This multicenter randomized clinical trial (International Randomized Trial to Evaluate the Effectiveness of the Portable Organ Care System Liver for Preserving and Assessing Donor Livers for Transplantation) was conducted between November 2016 and October 2019 at 20 US liver transplant programs. The trial compared outcomes for 300 recipients of livers preserved using either OCS (n = 153) or ICS (n = 147). Participants were actively listed for liver transplant on the United Network of Organ Sharing national waiting list.

          Interventions

          Transplants were performed for recipients randomly assigned to receive donor livers preserved by either conventional ICS or the OCS Liver initiated at the donor hospital.

          Main Outcomes and Measures

          The primary effectiveness end point was incidence of EAD. Secondary end points included OCS Liver ex vivo assessment capability of donor allografts, extent of reperfusion syndrome, incidence of IBC at 6 and 12 months, and overall recipient survival after transplant. The primary safety end point was the number of liver graft–related severe adverse events within 30 days after transplant.

          Results

          Of 293 patients in the per-protocol population, the primary analysis population for effectiveness, 151 were in the OCS Liver group (mean [SD] age, 57.1 [10.3] years; 102 [67%] men), and 142 were in the ICS group (mean SD age, 58.6 [10.0] years; 100 [68%] men). The primary effectiveness end point was met by a significant decrease in EAD (27 of 150 [18%] vs 44 of 141 [31%]; P = .01). The OCS Liver preserved livers had significant reduction in histopathologic evidence of ischemia-reperfusion injury after reperfusion (eg, less moderate to severe lobular inflammation: 9 of 150 [6%] for OCS Liver vs 18 of 141 [13%] for ICS; P = .004). The OCS Liver resulted in significantly higher use of livers from donors after cardiac death (28 of 55 [51%] for the OCS Liver vs 13 of 51 [26%] for ICS; P = .007). The OCS Liver was also associated with significant reduction in incidence of IBC 6 months (1.3% vs 8.5%; P = .02) and 12 months (2.6% vs 9.9%; P = .02) after transplant.

          Conclusions and Relevance

          This multicenter randomized clinical trial provides the first indication, to our knowledge, that normothermic machine perfusion preservation of deceased donor livers reduces both posttransplant EAD and IBC. Use of the OCS Liver also resulted in increased use of livers from donors after cardiac death. Together these findings indicate that OCS Liver preservation is associated with superior posttransplant outcomes and increased donor liver use.

          Trial Registration

          ClinicalTrials.gov Identifier: NCT02522871

          Abstract

          This multicenter randomized clinical trial compares the use of oxygenated portable normothermic machine perfusion of deceased donor livers for transplant vs conventional ischemic cold storage to assess liver function preservation and outcomes among recipients of a liver allograft.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          A randomized trial of normothermic preservation in liver transplantation

          Liver transplantation is a highly successful treatment, but is severely limited by the shortage in donor organs. However, many potential donor organs cannot be used; this is because sub-optimal livers do not tolerate conventional cold storage and there is no reliable way to assess organ viability preoperatively. Normothermic machine perfusion maintains the liver in a physiological state, avoids cooling and allows recovery and functional testing. Here we show that, in a randomized trial with 220 liver transplantations, compared to conventional static cold storage, normothermic preservation is associated with a 50% lower level of graft injury, measured by hepatocellular enzyme release, despite a 50% lower rate of organ discard and a 54% longer mean preservation time. There was no significant difference in bile duct complications, graft survival or survival of the patient. If translated to clinical practice, these results would have a major impact on liver transplant outcomes and waiting list mortality.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors.

            Translational studies in liver transplantation often require an endpoint of graft function or dysfunction beyond graft loss. Prior definitions of early allograft dysfunction (EAD) vary, and none have been validated in a large multicenter population in the Model for End-Stage Liver Disease (MELD) era. We examined an updated definition of EAD to validate previously used criteria, and correlated this definition with graft and patient outcome. We performed a cohort study of 300 deceased donor liver transplants at 3 U.S. programs. EAD was defined as the presence of one or more of the following previously defined postoperative laboratory analyses reflective of liver injury and function: bilirubin >or=10mg/dL on day 7, international normalized ratio >or=1.6 on day 7, and alanine or aspartate aminotransferases >2000 IU/L within the first 7 days. To assess predictive validity, the EAD definition was tested for association with graft and patient survival. Risk factors for EAD were assessed using multivariable logistic regression. Overall incidence of EAD was 23.2%. Most grafts met the definition with increased bilirubin at day 7 or high levels of aminotransferases. Of recipients meeting the EAD definition, 18.8% died, as opposed to 1.8% of recipients without EAD (relative risk = 10.7 [95% confidence interval: 3.6, 31.9] P < 0.0001). More recipients with EAD lost their grafts (26.1%) than recipients with no EAD (3.5%) (relative risk = 7.4 [95% confidence interval: 3.4, 16.3] P < 0.0001). Donor age and MELD score were significant EAD risk factors in a multivariate model. In summary a simple definition of EAD using objective posttransplant criteria identified a 23% incidence, and was highly associated with graft loss and patient mortality, validating previously published criteria. This definition can be used as an endpoint in translational studies aiming to identify mechanistic pathways leading to a subgroup of liver grafts with clinical expression of suboptimal function. (c) 2010 AASLD.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Ischaemia-reperfusion injury in liver transplantation--from bench to bedside.

              Ischaemia-reperfusion injury (IRI) in the liver, a major complication of haemorrhagic shock, resection and transplantation, is a dynamic process that involves the two interrelated phases of local ischaemic insult and inflammation-mediated reperfusion injury. This Review highlights the latest mechanistic insights into innate-adaptive immune crosstalk and cell activation cascades that lead to inflammation-mediated injury in livers stressed by ischaemia-reperfusion, discusses progress in large animal experiments and examines efforts to minimize liver IRI in patients who have received a liver transplant. The interlinked signalling pathways in multiple hepatic cell types, the IRI kinetics and positive versus negative regulatory loops at the innate-adaptive immune interface are discussed. The current gaps in our knowledge and the pathophysiology aspects of IRI in which basic and translational research is still required are stressed. An improved appreciation of cellular immune events that trigger and sustain local inflammatory responses, which are ultimately responsible for organ injury, is fundamental to developing innovative strategies for treating patients who have received a liver transplant and developed ischaemia-reperfusion inflammation and organ dysfunction.
                Bookmark

                Author and article information

                Journal
                JAMA Surg
                JAMA Surg
                JAMA Surgery
                American Medical Association
                2168-6254
                2168-6262
                5 January 2022
                March 2022
                5 January 2022
                : 157
                : 3
                : 189-198
                Affiliations
                [1 ]Massachusetts General Hospital, Boston
                [2 ]Henry Ford Transplant Institute, Detroit, Michigan
                [3 ]Houston Methodist, Houston, Texas
                [4 ]Virginia Commonwealth University, Richmond
                [5 ]University of Virginia, Charlottesville
                [6 ]Tampa General, Tampa, Florida
                [7 ]Johns Hopkins, Baltimore, Maryland
                [8 ]UT Health Science Center, San Antonio, Texas
                [9 ]University of Tennessee Health Science Center, Memphis
                [10 ]UCSF, San Francisco, California
                [11 ]Emory University Hospital, Atlanta, Georgia
                [12 ]University of Minnesota, Minneapolis
                [13 ]University of Washington, Seattle
                [14 ]The Ohio State University, Columbus
                [15 ]Scripps Clinic and Scripps Green Hospital, San Diego, California
                [16 ]University of California, San Diego, La Jolla
                [17 ]Montefiore Medical Center, Bronx, New York
                [18 ]Mount Sinai Health System, New York, New York
                [19 ]University of Nebraska Medical Center, Omaha
                [20 ]University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
                [21 ]University of Texas Southwestern Medical Center, Dallas
                Author notes
                Article Information
                Accepted for Publication: October 25, 2021.
                Published Online: January 5, 2022. doi:10.1001/jamasurg.2021.6781
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Markmann JF et al. JAMA Surgery.
                Corresponding Author: James F. Markmann, MD, PhD, Massachusetts General Hospital, 55 Fruit St, WHT 517, Boston, MA 02114-2696 ( jmarkmann@ 123456partners.org ).
                Author Contributions: Drs Markmann and MacConmara had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: Markmann, Abouljoud, Magliocca, Demetris, Kimura, Saharia, Agarwal, Moon, Maskin, MacConmara.
                Acquisition, analysis, or interpretation of data: Markmann, Abouljoud, Ghobrial, Bhati, Pelletier, Lu, Ottmann, Klair, Eymard, Roll, Pruett, Reyes, Black, Marsh, Schnickel, Kinkhabwala, Florman, Merani, Demetris, Kimura, Rizzari, Saharia, Levy, Cigarroa, Eason, Syed, Washburn, Parekh, Yeh, Vagefi, MacConmara.
                Drafting of the manuscript: Markmann, Abouljoud, Bhati, Kimura, Cigarroa, Parekh, MacConmara.
                Critical revision of the manuscript for important intellectual content: Abouljoud, Ghobrial, Bhati, Pelletier, Lu, Ottmann, Klair, Eymard, Roll, Magliocca, Pruett, Reyes, Black, Marsh, Schnickel, Kinkhabwala, Florman, Merani, Demetris, Rizzari, Saharia, Levy, Agarwal, Eason, Syed, Washburn, Parekh, Moon, Maskin, Yeh, Vagefi, MacConmara.
                Statistical analysis: Pruett, Saharia, Agarwal, MacConmara.
                Administrative, technical, or material support: Ghobrial, Bhati, Pelletier, Lu, Eymard, Roll, Magliocca, Schnickel, Kimura, Rizzari, Saharia, Levy, Syed, Parekh, Moon, Vagefi, MacConmara.
                Supervision: Markmann, Ghobrial, Klair, Eymard, Roll, Black, Merani, Kimura, MacConmara.
                Conflict of Interest Disclosures: Dr Bhati reported receiving personal fees from Intuitive Surgical outside the submitted work. Dr Pelletier reported receiving funding from Organ Recovery Systems outside the submitted work. Dr Lu reported receiving nonfinancial support from Tampa General Hospital during the conduct of the study. Dr Saharia reported receiving nonfinancial support from Houston Methodist Hospital during the conduct of the study. Dr Cigarroa reported receiving financial compensation from the Ford Foundation, Capital Group, Kleberg Foundation, and Clayton Foundation for Biomedical Research outside the submitted work. Dr MacConmara reported becoming employed by TransMedics after completion of the OCS Liver PROTECT randomized clinical trial and submission of the final manuscript. No other disclosures were reported.
                Funding/Support: This study was supported by TranMedics Inc.
                Role of the Funder/Sponsor: TranMedics led the design of the trial protocol in collaboration with senior investigators; was responsible for data collection and generating the final study report; assisted the authors in drafting and reviewing figures, tables, and corresponding descriptions; provided manuscript text suggestions to ensure accuracy of the data presented; and at the request of the authors, provided additional analyses of the trial data to help address study investigator questions. TranMedics Inc had no role in the clinical interpretation of the data or the decision to submit the manuscript for publication.
                Data Sharing Statement: See Supplement 3.
                Additional Contributions: We thank our surgical colleagues and study coordinators from all participating centers for their efforts to successfully complete this trial. David Cronin, MD, PhD, University of Chicago, Chicago, Illinois, and Kareem Abu Elmagd, MD, PhD, Cleveland Clinic, Weston, Florida, supported this study in their roles as chairman of the clinical events committee and the chairman of the data and safety monitoring board, respectively. Ahmed Elbetanony, MB, BCh, TransMedics, Andover, Massachusetts, supported the trial centers during enrollment. No one received financial compensation for the stated contribution.
                Article
                soi210103
                10.1001/jamasurg.2021.6781
                8733869
                34985503
                d38288b0-1fa8-488f-8d1c-d339b78e5387
                Copyright 2022 Markmann JF et al. JAMA Surgery.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 6 July 2021
                : 25 October 2021
                Funding
                Funded by: TranMedics Inc
                Categories
                Research
                Research
                Original Investigation
                Online First

                Comments

                Comment on this article